Breo Ellipta is a novel combination inhaler indicated for the maintenance of COPD, including chronic bronchitis and/or emphysema.

BREO ELLIPTA will help patients breathe better day-to-day and reduce the risk of future exacerbations, with a once-daily inhalation." ...

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction ...

BREO® is administered once daily via the dry powder inhaler called ELLIPTA®, which is also used across a range of other approved respiratory medicines in the GSK portfolio.

Breo Ellipta is our second asthma treatment to be approved in the US in the past year, and now provides physicians with a range of treatment options delivered via the Ellipta inhaler to meet the ...

BREO™ ELLIPTA™ is also not indicated for the relief of acute bronchospasm in COPD. Patients should be prescribed a rapid onset, short duration inhaled bronchodilator to relieve acute symptoms.

Breo Ellipta should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of chronic obstructive pulmonary disease or asthma or used for the relief of ...